“…Patients treated with eptinezumab or placebo, presented no clinically significant differences in vital signs, 12-lead ECGs, or laboratory safety data. Likewise, the most commonly reported AEs for eptinezumab, at an incidence of ≥2%, were hypersensitivity reactions (hypersensitivity, urticaria, flushing/hot flush, rash, and pruritus), nasopharyngitis (6.3%), upper respiratory infection (4%), nausea (3.4%), arthralgia (2.3%), urinary tract infection (3.1%), dizziness (2.6%), fatigue (2%) and anxiety (2%) [ 84 , 85 , 88 ].…”